Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib reduces vessel wall volume and increases small pulmonary artery vessel volume: Insights from AI-driven CT imaging analysis

Monday, September 29, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the positive effects of Seralutinib on pulmonary artery health, highlighting its ability to reduce vessel wall volume and increase the volume of small pulmonary arteries. These findings are supported by AI-driven CT imaging analysis, suggesting a significant advancement in the treatment of pulmonary arterial hypertension (PAH). The results indicate potential benefits for patients suffering from related conditions.
Price reaction · baseline $2.82 (2025-09-29 close) · hit after-hours · 1 other GOSS headline(s) in the window, move may be shared
day 0 close
-6.7%
day 1 · peak
-11.7%
day 3
-8.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows promise in reducing vessel wall volume.
  • Increases in small pulmonary artery vessel volume are observed.
  • AI-driven CT imaging analysis provides valuable insights.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib reduces vessel wall volume and increases small pulmonary artery vessel volume: Insights from AI-driven CT imaging analysis
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is the effect of Seralutinib on vessel wall volume?

Seralutinib reduces vessel wall volume, indicating potential benefits for pulmonary artery health.

How does Seralutinib affect small pulmonary artery volume?

Seralutinib increases the volume of small pulmonary arteries, which is beneficial for patients.

What technology was used to analyze the effects of Seralutinib?

AI-driven CT imaging analysis was utilized to assess the effects of Seralutinib.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib pulmonary artery PAH CT imaging
Last updated: Sep 29, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →